Answers are grounded in this paper and cite their sources.
The incidence of non-Hodgkin's lymphomas continues to rise and the number of deaths attributable to these malignancies currently rank in the top five causes of cancer-related deaths in the United States. Recent insights into the pathogenesis and molecular characterization of these disorders have led to improvements in a clinicopathologically relevant classification system, as well as in the ability to accurately diagnose specific entities. Several new treatment modalities have been developed which may improve the outcome for selected patients. A better understanding of the biology of non-Hodgkin's lymphomas will hopefully translate into different therapies with improved outcomes. This article describes a new system for classifying the non-Hodgkin's lymphomas, highlights key aspects of the pathogenesis of non-Hodgkin's lymphomas and briefly reviews clinical and therapeutic approaches to the most common of these lymphomas.
No takes yet. Share an insight, caveat, or question.
Hauke et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: